Welcome!

News Feed Item

2013 Japanese Hospital Microbiology Testing Market

NEW YORK, Jan. 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

2013 Japanese Hospital Microbiology Testing Market

http://www.reportlinker.com/p01083065/2013-Japanese-Hospital-Microbiolog...

This new report from Venture Planning Group contains 891 pages, 75 tables, and presents a comprehensive analysis of the Japanese hospital microbiology testing market, including:

·         Major issues pertaining to the Japanese hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.

·         Current scientific views on definition, epidemiology, and etiology of major infectious diseases and microorganisms.

·         Volume and sales forecasts for 80 microbiology tests performed in Japanese hospital laboratories.

·         Instrumentation technologies and feature comparison of leading analyzers.

·         Sales and market shares of leading suppliers.

·         Emerging diagnostic technologies and their potential market applications.

·         Product development opportunities.

·         Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

·         Business opportunities and strategic recommendations for suppliers.

Contains 891 pages and 75 tables

 

 

 

Table of Contents

 

Introduction

Worldwide Market and Technology Overview

A. Major Infectious Disease Tests

1. AIDS

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

2. Adenovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

d. Adeno-Associated Viruses(AAV)

3. Aeromonas

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

4. Anthrax/Bacillus Anthracis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

5. Arboviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

6. Babesiosis

a. Background

7. Bacillary Epithelioid Angiomatosis (BEA)

And Other Bartonella (Rochalimaea)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

8. Blastocystis Hominis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

9. Brucella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

10. Campylobacter

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

11. Candida

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

12. Chagas Disease

a. Background

13. Chancroid

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

14. Chlamydia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

15. Clostridium Difficile

a. Background

b. Diagnostic Tests

c. Drugs and Vaccines

16. Coronaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

17. Coxsackieviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

18. Creutzfeldt-Jakob's Disease

a. Background

b. Diagnostic Tests

c. Vaccines

19. Cryptosporidium Parvum

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

20. Cyclospora Cayetanensis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

21. Cytomegalovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

22. Ebola Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

23. E. Coli

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

24. EchoVirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

25. Encephalitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

26. Enteroviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

27. Epstein-Barr Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

28. Giardia Lamblia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

29. Gonorrhea

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

30. Granuloma Inguinale

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

31. Hantavirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

32. Helicobacter Pylori

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

33. Hepatitis

a. Background

b. Hepatitis A

c. Hepatitis B

d. Hepatitis C

e. Vaccines and Drugs

34. Herpes Simplex Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

35. Human Herpes Virus-6 (HHV-6)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

36. Influenza Viruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

37. Legionella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

38. Lyme Disease

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

39. Lymphogranuloma Venereum (LGV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

40. Malaria

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

41. Measles (Rubeola)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

42. Meningitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

43. Microsporidium

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

44. Mononucleosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

45. Mumps

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

46. Mycoplasma

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

47. Papillomaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

48. Parvovirus B19

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

49. Pneumonia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

50. Polyomaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

51. Pseudomonas Aeruginosa

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

52. Rabies

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

53. Respiratory Syncytial Virus (RSV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

54. RhinoViruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

55. RotaVirus (REOVIRUS)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

56. Rubella(MEASLES)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

57. Salmonellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

58. Septicemia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

59. Shigellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

60. Staphylococcus Aureus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

61. Streptococci

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

62. Syphilis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

63. Toxoplasmosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

64. Trichomonas Vaginalis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

65. Tuberculosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

66. Vibrio

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

67. West Nile Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

68. Yersina

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

B. Instrumentation Review of Leading Analyzers Marketed

by Abbott, Beckman Coulter/Danaher, BioMerieux,

Ortho-Clinical Diagnostics, Roche, Siemens, Tosoh,

Wallac and Other Suppliers

C. Emerging Diagnostic Technologies

1. Molecular Diagnostics

2. Monoclonal Antibodies

3. Immunoassays

4. Differential Light Scattering

5. Information Technology

6. Artificial Intelligence

7. Liposomes

8. Flow Cytometry

9. Chromatography

10. Diagnostic Imaging

11. Gel Microdroplets

12. Other

Japan

A. Executive Summary

B. Business Environment

C. Market Structure

D. Market Size, Growth and Major Suppliers

Major Product Development Opportunities

A. Instrumentation

B. Reagent Kits and Test Systems/Panels

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies for Decentralized

Testing Markets

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Assessments

- Abbott

- Affymetrix

- Beckman Coulter/Danaher

- Becton Dickinson

- bioMerieux

- Bio-Rad

- Cepheid

- Diamedix

- DiaSorin

- Eiken Chemical

- Enzo Biochem

- Fujirebio

- Gen-Probe

- Hologic

- ID Biomedical

- Innogenetics/Solvay

- Kreatech

- Life Technology

- Lonza

- Nanogen/Elitech

- Novartis Diagnostics

- Ortho-Clinical Diagnostics

- Qiagen

- Roche

- Scienion

- Sequenom

- SeraCare

- Siemens

- Takara Bio

- Thermo Fisher

- Wallac

- Wako

 

 

 

List of Tables

 

Major Companies Developing or Marketing AIDS Tests

Major Companies Developing or Marketing Adenovirus

Tests

Major Companies Developing or Marketing Bartonella

Tests

Major Companies Developing or Marketing

Campylobacter Tests

Major Companies Developing or Marketing Candida

Tests

Major Companies Developing or Marketing Chlamydia

Tests

Major Companies Developing or Marketing Clostridium

Tests

Major Companies Developing or Marketing Coronavirus

Tests

Major Companies Developing or Marketing Cryptosporidium

Tests

Major Companies Developing or Marketing CMV Tests

Major Companies Developing or Marketing Echovirus

Tests

Major Companies Developing or Marketing Enterovirus

Tests

Major Companies Developing or Marketing EBV Tests

Major Companies Developing or Marketing Giardia

Tests

Major Companies Developing or Marketing Gonorrhea

Tests

Major Companies Developing or Marketing Hantavirus

Tests

Major Companies Developing or Marketing Helicobacter

Pylori Tests

Major Companies Developing or Marketing Hepatitis

Tests

Major Companies Developing or Marketing Herpes

Tests

Major Companies Developing or Marketing Influenza

Tests

Major Companies Developing or Marketing Legionella

Tests

Major Companies Developing or Marketing Lyme Disease

Tests

Major Companies Developing or Marketing Lymphogranuloma

Tests

Major Companies Developing or Marketing Malaria

Tests

Major Companies Developing or Marketing Measles

Tests

Major Companies Developing or Marketing Meningitis

Tests

Major Companies Developing or Marketing Microsporidium

Tests

Major Companies Developing or Marketing

Mononucleosis Tests

Major Companies Developing or Marketing Mumps Tests

Major Companies Developing or Marketing Mycoplasma

Tests

Major Companies Developing or Marketing Papilloma

Virus Tests

Major Companies Developing or Marketing Parvovirus

Tests

Major Companies Developing or Marketing Pneumonia

Tests

Major Companies Developing or Marketing RSV Tests

Major Companies Developing or Marketing Rotavirus

Tests

Major Companies Developing or Marketing Rubella

Tests

Major Companies Developing or Marketing Salmonella

Tests

Major Companies Developing or Marketing Septicemia

Tests

Major Companies Developing or Marketing Shigella

Tests

Major Companies Developing or Marketing Staphylococci

Tests

Major Companies Developing or Marketing

Streptococci Tests

Major Companies Developing or Marketing Syphilis

Tests

Major Companies Developing or Marketing Toxoplasmosis

Tests

Major Companies Developing or Marketing Trichomonas

Tests

Major Companies Developing or Marketing Tuberculosis

Tests

Major Companies Developing or Marketing West Nile

Tests

Major Companies Developing or Marketing Yersinia Tests

Japan Summary Table

All Infectious Diseases Test Volume and Diagnostics

Sales Forecast by Market Segment

Japan

Hospital Laboratories Performing Infectious Disease

Tests by Bed Size

Japan

Hospital Laboratories Infectious Disease Test

Volume Forecast

Japan

Hospital Laboratories Infectious Disease Diagnostics

Market Forecast

Japan

AIDS Testing Market Diagnostics Sales

by Major Supplier

Japan

Campylobacter Testing Market Diagnostics Sales

by Major Supplier

Japan

Candida Testing Market Diagnostics Sales

by Major Supplier

Japan

Chlamydia Testing Market Diagnostics Sales

by Major Supplier

Japan

CMV Testing Market Diagnostics Sales

by Major Supplier

Japan

Gonorrhea Testing Market Diagnostics Sales

by Major Supplier

Japan

Hepatitis Testing Market Diagnostics Sales

by Major Supplier

Japan

Hepatitis C Testing Market Diagnostics Sales

by Major Supplier

Japan

Herpes Testing Market Diagnostics Sales

by Major Supplier

Japan

Legionella Testing Market Diagnostics Sales Forecast

by Major Supplier

Japan

Meningitis Testing Market Diagnostics Sales

by Major Supplier

Japan

Mononucleosis Testing Market Diagnostics Sales

by Major Supplier

Japan

Mycoplasma Testing Market Diagnostics Sales

by Major Supplier

Japan

Pneumonia Testing Market Diagnostics Sales

by Major Supplier

Japan

RSV Testing Market Diagnostics Sales by Major Supplier

Japan

Rotavirus Testing Market Diagnostics Sales

by Major Supplier

Japan

Rubella Testing Market Diagnostics Sales

by Major Supplier

Japan

Septicemia Testing Market Diagnostics Sales

by Major Supplier

Japan

Shigella Testing Market Diagnostics Sales

by Major Supplier

Japan

Streptococci Testing Market Diagnostics Sales

by Major Supplier

Japan

Syphilis Testing Market Diagnostics Sales

by Major Supplier

Japan

Toxoplasmosis Testing Market Diagnostics Sales

by Major Supplier

Japan

Trichomonas Testing Market Diagnostics Sales

by Major Supplier

Japan

Tuberculosis Testing Market Diagnostics Sales

by Major Supplier

 

 

 

To order this report:

In_Vitro_Diagnostic Industry: 2013 Japanese Hospital Microbiology Testing Market

 

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Codigm is based on the cloud and we are here to explore marketing opportunities in America. Our mission is to make an ecosystem of the SW environment that anyone can understand, learn, teach, and develop the SW on the cloud," explained Sung Tae Ryu, CEO of Codigm, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, discussed how by using ne...
"CA has been doing a lot of things in the area of DevOps. Now we have a complete set of tool sets in order to enable customers to go all the way from planning to development to testing down to release into the operations," explained Aruna Ravichandran, Vice President of Global Marketing and Strategy at CA Technologies, in this SYS-CON.tv interview at DevOps Summit at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"There's plenty of bandwidth out there but it's never in the right place. So what Cedexis does is uses data to work out the best pathways to get data from the origin to the person who wants to get it," explained Simon Jones, Evangelist and Head of Marketing at Cedexis, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...